Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual and Recell Ice for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method; and Careveam for treating skin ailment by using ultraviolet light. Further, the company offers Neurakin cream for acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea dermatitis, perioral dermatitis, herpes zoster, and acne vulgaris. It also exports its products to approximately 60 countries, including Japan, Thailand, and Brazil. Medytox, Inc. has partnership with Dyadic International, Inc. to develop vaccines against COVID-19 variants. The company was founded in 2000 and is headquartered in Cheongju, South Korea.
Medy-Tox Dividend Announcement
• Medy-Tox announced a annually dividend of ₩1100.00 per ordinary share which will be made payable on 2024-10-25. Ex dividend date: 2024-09-27
• Medy-Tox annual dividend for 2024 was ₩1100.00
• Medy-Tox annual dividend for 2023 was ₩952.38
• Medy-Tox's trailing twelve-month (TTM) dividend yield is 0.88%
• Medy-Tox's payout ratio for the trailing twelve months (TTM) is 71.97%
• Medy-Tox's dividend growth over the last five years (2018-2023) was -11.87% year
• Medy-Tox's dividend growth over the last ten years (2013-2023) was 1.67% year
Medy-Tox Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-09-27 | ₩1100.00 | annually | 2024-10-25 |
2023-09-26 | ₩952.38 | annually | 2023-10-25 |
2022-09-29 | ₩1050.00 | annually | 2022-10-31 |
2021-09-29 | ₩1102.50 | annually | |
2020-09-28 | ₩1050.00 | annually | 2020-10-21 |
2019-09-27 | ₩747.39 | annually | 2019-10-30 |
2018-12-27 | ₩1064.99 | annually | |
2018-09-27 | ₩726.33 | annually | 2018-10-30 |
2017-12-27 | ₩1129.84 | annually | 2018-04-18 |
2017-09-28 | ₩645.63 | annually | 2017-10-30 |
2016-12-28 | ₩1049.14 | annually | |
2016-09-29 | ₩564.92 | annually | |
2015-12-29 | ₩887.74 | annually | |
2015-09-25 | ₩484.22 | annually | |
2014-12-29 | ₩807.03 | annually | |
2014-09-29 | ₩403.52 | annually | |
2013-12-27 | ₩807.03 | annually |
Medy-Tox Dividend per year
Medy-Tox Dividend growth
Medy-Tox Dividend Yield
Medy-Tox current trailing twelve-month (TTM) dividend yield is 0.88%. Interested in purchasing Medy-Tox stock? Use our calculator to estimate your expected dividend yield:
Medy-Tox Financial Ratios
Medy-Tox Dividend FAQ
Other factors to consider when evaluating Medy-Tox as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Medy-Tox stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Medy-Tox's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Medy-Tox publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Medy-Tox distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Medy-Tox are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Medy-Tox sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Medy-Tox distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Medy-Tox declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Medy-Tox's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Medy-Tox's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.